|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5030453A
(en)
|
1983-03-24 |
1991-07-09 |
The Liposome Company, Inc. |
Stable plurilamellar vesicles
|
|
US5998203A
(en)
|
1996-04-16 |
1999-12-07 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
|
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US5891467A
(en)
|
1997-01-31 |
1999-04-06 |
Depotech Corporation |
Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
|
|
ES2241192T3
(es)
|
1997-12-17 |
2005-10-16 |
MERCK & CO., INC. (A NEW JERSEY CORP.) |
Antagonistas del receptor de integrina.
|
|
US6017926A
(en)
|
1997-12-17 |
2000-01-25 |
Merck & Co., Inc. |
Integrin receptor antagonists
|
|
EP2314700A1
(en)
|
1999-01-28 |
2011-04-27 |
Medical College of Georgia Research Institute, Inc |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
|
|
DE60040274D1
(de)
|
1999-03-10 |
2008-10-30 |
Phogen Ltd |
Verabreichung von nukleinsäuren und proteinen an zellen
|
|
US6309401B1
(en)
|
1999-04-30 |
2001-10-30 |
Vladimir Redko |
Apparatus and method for percutaneous implant of a paddle style lead
|
|
US8137695B2
(en)
|
2006-08-18 |
2012-03-20 |
Arrowhead Madison Inc. |
Polyconjugates for in vivo delivery of polynucleotides
|
|
EP1272630A2
(en)
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
|
US6680068B2
(en)
|
2000-07-06 |
2004-01-20 |
The General Hospital Corporation |
Drug delivery formulations and targeting
|
|
US20080188430A1
(en)
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
|
WO2002100435A1
(en)
|
2001-06-11 |
2002-12-19 |
Centre Hospitalier Universitaire De Montreal |
Compositions and methods for enhancing nucleic acid transfer into cells
|
|
CA2456977C
(en)
|
2001-08-16 |
2011-06-07 |
The Trustees Of The University Of Pennsylvania |
Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
|
|
DE10230997A1
(de)
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
|
|
US7901708B2
(en)
|
2002-06-28 |
2011-03-08 |
Protiva Biotherapeutics, Inc. |
Liposomal apparatus and manufacturing methods
|
|
MXPA05003287A
(es)
|
2002-09-28 |
2005-07-05 |
Massachusetts Inst Technology |
Influenza terapeutica.
|
|
EP2305812A3
(en)
|
2002-11-14 |
2012-06-06 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
ES2343318T3
(es)
|
2002-11-26 |
2010-07-28 |
University Of Massachusetts |
Administracion de arnsis.
|
|
ES2559828T3
(es)
|
2003-07-16 |
2016-02-16 |
Protiva Biotherapeutics Inc. |
ARN de interferencia encapsulado en lípidos
|
|
CN1845993B
(zh)
|
2003-08-28 |
2010-06-23 |
诺瓦提斯公司 |
具有平端和3＇修饰的干扰rna双链体
|
|
AU2005222965B8
(en)
|
2004-03-15 |
2010-07-01 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
EP1752536A4
(en)
|
2004-05-11 |
2008-04-16 |
Alphagen Co Ltd |
POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
|
|
EP1791567B1
(en)
|
2004-08-10 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
Chemically modified oligonucleotides
|
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
WO2007107162A2
(en)
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
BRPI0811170B8
(pt)
|
2007-05-22 |
2021-05-25 |
Arcturus Therapeutics Inc |
oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
|
|
EP2186528B1
(en)
|
2007-08-06 |
2014-03-19 |
Senju Pharmaceutical Co., Ltd. |
Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
|
|
WO2009082817A1
(en)
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
|
CN102026671B
(zh)
*
|
2008-03-14 |
2014-09-03 |
Visen医药公司 |
整联蛋白靶向试剂及使用其的体内和体外成像方法
|
|
WO2009114836A1
(en)
|
2008-03-14 |
2009-09-17 |
Genomic Health, Inc. |
Gene expression markers for prediction of patient response to chemotherapy
|
|
EP2265283B1
(en)
|
2008-03-18 |
2014-09-03 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
|
CN102037123A
(zh)
|
2008-04-04 |
2011-04-27 |
卡兰多制药股份有限公司 |
Epas1抑制剂的组合物和用途
|
|
AU2009336191B2
(en)
|
2008-12-18 |
2017-08-24 |
Novo Nordisk A/S |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
WO2011076807A2
(en)
|
2009-12-23 |
2011-06-30 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
DK2539451T3
(da)
|
2010-02-24 |
2016-04-04 |
Arrowhead Res Corp |
Sammensætninger til målrettet tilførsel af siRNA
|
|
KR101223660B1
(ko)
|
2010-05-20 |
2013-01-17 |
광주과학기술원 |
ＨＩＦ－２α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
EP2652134B1
(en)
|
2010-12-17 |
2017-03-01 |
Arrowhead Pharmaceuticals, Inc. |
Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
|
|
ES2605990T3
(es)
|
2010-12-29 |
2017-03-17 |
F. Hoffmann-La Roche Ag |
Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
|
|
WO2012174224A2
(en)
|
2011-06-17 |
2012-12-20 |
Calando Pharmaceuticals, Inc. |
Methods for administering nucleic acid-based therapeutics
|
|
WO2013032829A1
(en)
|
2011-08-26 |
2013-03-07 |
Arrowhead Research Corporation |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
JP2015515530A
(ja)
|
2012-04-18 |
2015-05-28 |
アローヘッド リサーチ コーポレイション |
インビボ核酸送達のためのポリ（アクリラート）ポリマー
|
|
SG10201706960TA
(en)
|
2013-02-28 |
2017-10-30 |
Arrowhead Res Corp |
Organic compositions to treat epas1-related diseases
|
|
US9504747B2
(en)
|
2013-03-08 |
2016-11-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
WO2015021092A1
(en)
|
2013-08-07 |
2015-02-12 |
Arrowhead Research Corporation |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
US20160272970A1
(en)
|
2015-03-17 |
2016-09-22 |
Arrowhead Madison Inc. |
RNA Interference Agents
|
|
HK1252852A1
(zh)
*
|
2015-05-29 |
2019-06-06 |
Arrowhead Pharmaceuticals, Inc. |
阻止HIF2α基因表达的组合物及方法
|
|
JP7420727B2
(ja)
|
2018-02-17 |
2024-01-23 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
トリアルキン結合剤及び使用方法
|
|
US20210093725A1
(en)
|
2018-04-27 |
2021-04-01 |
Arrowhead Pharmaceuticals, Inc. |
Integrin targeting ligands and uses thereof
|